BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: A pilot study in a Chinese cohort

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1171-1176

  Jiang, Xiao Bing ^a   He, Dong Sheng ^a   Mao, Zhi Gang ^a   Fan, Xiang ^a   Lei, Ni ^b   Hu, Bin ^a   Song, Bing Bing ^b   Zhu, Yong Hong ^b   Wang, Hai Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apolipoprotein; Insulin resistance; Pituitary adenoma; Prolactin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; INSULIN; LIPID; PROLACTIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CHINESE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; PILOT STUDY; PRIORITY JOURNAL; PROLACTINOMA; RISK ASSESSMENT; RISK FACTOR; WAIST CIRCUMFERENCE; WEIGHT GAIN; ASIAN; FOLLOW UP; METABOLISM; METABOLOME; PROGNOSIS;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLOME; PILOT PROJECTS; PROGNOSIS; PROLACTINOMA;

MLCS; MLOWN;

EID: 84877142909     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0660-z     Document Type: Article

References (24)

1. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769-75.
2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273-88.
3. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010;362:1219-26.
4. dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800-5.
5. Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64:366-70.
6. Berinder K, Nystrom T, Hoybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199-207.
7. Johnston DG, Alberti KG, Nattrass M, et al. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13:361-8.
8. Ben-Jonathan N, Hugo ER, Brandebourg TD, et al. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110-6.
9. Park S, Kim DS, Daily JW, et al. Serum prolactin concentrations determine whether they improve or impair beta-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev. 2011;27:564-74.
10. Bahceci M, Tuzcu A, Bahceci S, et al. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003;26:655-9.
11. Doumatey AP, Lashley KS, Huang H, et al. Relationships among obesity, inflammation, and insulin resistance in African Americans and West Africans. Obesity (Silver Spring). 2010;18:598-603.
12. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med. 2006;259:493-519.
13. Enkhmaa B, Anuurad E, Zhang Z, et al. Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans. Am J Cardiol. 2010;106:1264-9.
14. Dahlen EM, Lanne T, Engvall J, et al. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with type 2 diabetes. Diabet Med. 2009;26:384-90.
15. Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM, et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J Endocrinol. 2011;208:107-17.
16. Carnevale SG, Pedrazzoli R, Onolfo S, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis. 2011;21:406-11.
17. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in us non-diabetic subjects. Eur Heart J. 2007;28:2637-43.
18. Kelishadi R, Cook SR, Amra B, et al. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis. 2009;204:538-43.
19. de Assunção Alves Rodrigues LF, Campos SM, Miranda PA, et al. Prolactinoma: a condition associated with hypoadiponectinemia. Horm Metab Res. 2012;44:832-8.
20. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62.
21. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157-63.
22. Schmid C, Goede DL, Hauser RS, et al. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254-8.
23. Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77-84.
24. Xi B, Liang Y, He T, et al. Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993-2009. Obes Rev. 2012;13:287-96.